The FDA continues to accelerate promising oncology therapies, granting fast-track designations to several innovative candidates in April 2026. These designations highlight the urgency of advancing treatments for cancers with high unmet medical need.
Industry Highlights (from the article)
- PAS-004 (Pasithea Therapeutics) – MEK inhibitor for NF1-associated plexiform neurofibromas.
- A2B543 (A2 Biotherapeutics) – Autologous CAR T-cell therapy for solid tumors.
- CTIM-76 (Context Therapeutics) – Bispecific antibody for platinum-resistant ovarian cancer.
- SIM0505 (NextCure) – ADC for ovarian cancer.
- CT-P71 (Celltrion) – ADC targeting Nectin-4 for urothelial carcinoma.
- Daretabart (Renaissance Pharma) – Anti-GD2 monoclonal antibody for neuroblastoma.
- OPN-6602 (Opna Bio) – Dual EP300/CBP inhibitor for multiple myeloma.
- Lunresertib + Zedoresertib (Debiopharm) – Combination therapy for ovarian cancer.
- BBO-11818 (BridgeBio Oncology) – KRAS inhibitor for pancreatic cancer.
- iSCIB1+ (Scancell Holdings) – Immunotherapy for advanced melanoma.
Anveta’s Perspective
At Anveta Therapeutics, we are inspired by the FDA’s commitment to accelerating oncology innovation. These fast-track designations underscore the importance of translating breakthrough science into therapies that reach patients faster. Our mission is to advance differentiated small-molecule therapeutics through early clinical development, ensuring that patients benefit from innovation without delay. By monitoring and engaging with these regulatory milestones, we remain aligned with the global oncology ecosystem and committed to shaping the future of cancer care.